NCT04970576View on ClinicalTrials.gov

Rivaroxaban in Left Ventricular Thrombus

PHASE4CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Acute Coronary SyndromeLeft Ventricular Thrombus
Interventions
DRUG

Rivaroxaban

Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks

DRUG

Warfarin

Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks

Trial Locations (1)

75510

National Institute of Cardiovascular Diseases, Karachi

All Listed Sponsors
lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER